Aptose Biosciences Inc. (APS.TO)

1,6800 +0,0400 (+2,44%) Börsenschluss: 01:16PM EDT

Aptose Biosciences Inc.

251 Consumers Road
Suite 1105
Toronto, ON M2J 4R3
Canada
647 479 9828
https://www.aptose.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 35

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. William G. Rice Ph.D.	Chairman, President & CEO	890,6k	N/A	1959
Mr. Fletcher Payne	Senior VP, CFO, Chief Business Officer & Secretary	626,63k	N/A	1963
Dr. Rafael Bejar M.D., Ph.D.	Senior VP & Chief Medical Officer	816,41k	N/A	1972
Dr. Marc Wiles Ph.D.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Mr. Brooks Ensign M.B.A.	VP & Controller	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Corporate Governance

Aptose Biosciences Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 9. Die grundlegenden Scores sind Audit: 9, Vorstand: 8, Shareholderrechte: 7, Kompensation: 9.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.